Replies to post #209955 on Biotech Values

[DewDiligence]

Repatha-CVOT fallout…

AMGN -7%
REGN -5% (SNY -1%)
MDCO -21% (ALNY -3%)
ESPR -19%

Deep lowering of LDL (above what can be done with a statin) is taking a hit, generally.

[DewDiligence]

AMGN offers “money-back” pricing on Repatha for US payers:

http://finance.yahoo.com/news/landmark-outcomes-study-shows-repatha-130000812.html

Amgen to Offer Innovative Refund Contracts in the U.S.

To underscore the Company's conviction around these outcomes results, Amgen will offer additional contracting options in the U.S. to payers willing to remove access barriers. These options include one that offers a refund of the cost of Repatha for all of their eligible patients who have a heart attack or stroke.

AMGN’s offer seems more like an act of desperation than a sign of confidence in the CVOT data. For payers, offering unfettered access to Repatha in return for the money-back option seems like a very bad tradeoff.